UTMD offers defensive value through 60% gross margins, net cash equal to 37.6% of market cap, and litigation-driven upside if revenue stabilizes and direct biopharma sales gain traction.
Utah Medical Products Inc (UTMD) is an established, debt-free medical device manufacturer that specializes in producing high-margin, consumable clinical tools for women and babies.[1, 2, 3] The corporate revenue model is anchored in the development, manufacture, and direct distribution of proprietary, disposable medical devices designed for specialized hospital departments, particularly neonatal intensive care units (NICUs), labor and delivery wards, gynecological surgery rooms, and critical care units.[4, 5] The company operates as a single operating segment but manages its product categories under four core classifications: Gynecology/Electrosurgery/Urology, Neonatal Intensive Care, Blood Pressure Monitoring and Accessories (Critical Care), and Obstetrics.[4, 6]
FY2025 Consolidated Revenue: $38.52 Million
|
+-------------------------+-------------+-------------+-------------------------+
| | | |
Gynecology Neonatal Critical Care Obstetrics
$19.72M (51%) $8.01M (21%) $6.79M (18%) $4.00M (10%)
| | | |
Key Product: Key Product: Key Product: Key Product:
Filshie Clip DISPOSA-HOOD Deltran Transducer INTRAN PLUS Catheter
Consolidated revenues in fiscal year 2025 totaled $38.52 million, down 5.8% from $40.90 million in fiscal year 2024 and 23.3% from $50.22 million in fiscal year 2023.[7, 8, 9] Trade revenues generated outside the United States (OUS) represented 41% ($15.758 million) of total consolidated sales in fiscal year 2025, reflecting a steady decline from 43% ($17.458 million) in fiscal year 2024 and 44% ($22.020 million) in fiscal year 2023.[4] The remaining 59% of revenue is generated domestically within the United States.[4, 7] Geographically, the company operates standalone physical manufacturing facilities in Midvale, Utah; Athlone, Ireland; and Romsey, United Kingdom, and maintains distribution offices in Mississauga, Canada, and Castle Hill, Australia.[4, 10]
UTMD's core products consist of clinically proven consumables that are deeply integrated into daily hospital operations.[11] These include the Filshie® Clip System for permanent female surgical sterilization, the DISPOSA-HOOD™ infant respiratory hood, the INTRAN® PLUS intrauterine pressure catheter system, the BT-Cath® postpartum balloon tamponade, and the Deltran® disposable blood pressure transducer.[4, 11, 12] The primary customer base consists of clinical procurement managers, hospital purchasing departments, OB/GYN surgeons, and neonatologists, alongside biopharmaceutical manufacturing firms that purchase specialized high-pressure transducers.[12, 13, 14]
Clinicians choose UTMD over cheaper alternatives because its products are designed to solve specific operational and safety problems.[11] The company's focus on clinical safety is supported by decades of peer-reviewed clinical history and low complication rates.[11, 12] For example, the Filshie Clip System has been used in over 12 million applications globally since its introduction in 1982.[12] Hospital procurement departments choose UTMD because its disposable systems, such as the single-use Sterishot® II applicator, eliminate corporate liabilities related to hospital-acquired infections, device damage, and post-surgical cleaning costs.[12]
UTMD's operational success relies on the continuous manufacture of proprietary, disposable medical devices.[11] Each product category has distinct engineering characteristics:
UTMD's defensive business moat is built on high switching costs, regulatory barriers, and owned physical assets.[10, 11, 15] These factors limit customer churn and protect profitability:
The company addresses several expanding niches within the global medical technology industry:
| Market Niche | Baseline Valuation | Projected Growth Target | Compound Annual Growth Rate (CAGR) | Source |
|---|---|---|---|---|
| Global Obstetrical Devices | $8.52 Billion (2024) | $12.18 Billion (2034) | 3.64% (2025–2034) | [17] |
| Global Electrosurgical Devices | $8.92 Billion (2025) | $18.64 Billion (2035) | 7.60% (2026–2035) | [18] |
| Global Fetal/Neonatal Care Equipment | $10.10 Billion (2025) | $17.70 Billion (2034) | 6.30% (2026–2034) | [19] |
| Advanced Medical Stopcocks | $0.97 Billion (2023) | $1.45 Billion (2031) | 6.80% (2024–2031) | [20] |
UTMD operates alongside a range of medical technology companies.[9, 13, 17] Direct competitors in obstetrical and neonatal care include industry leaders such as CooperSurgical, Becton Dickinson, Philips Healthcare, GE HealthCare, Masimo, and Natus Medical.[17, 19] In the pressure transducer and critical care segments, the company competes with Merit Medical Systems, Teleflex, ICU Medical, Edwards Lifesciences, and B. Braun.[9, 21]
Historically, UTMD has prioritized protecting high profit margins and cash flow over gaining market share through heavy discounting.[5] The company is losing ground in high-volume OEM relationships due to PendoTECH's decision to in-source its sensor manufacturing and the cancellation of its former blood pressure kit distributor in China.[1, 7, 14] However, UTMD is holding ground in direct clinical sales.[7] The business has maintained stable pricing power, offsetting declining OEM volumes by converting legacy OEM business into direct, higher-margin biopharma distribution.[7, 14]
UTMD reported its Q1 2026 financial results on April 23, 2026, for the period ending March 31, 2026.[22, 23] The company filed its Form 10-Q on May 12, 2026.[24] Q1 2026 performance highlights are detailed below compared to the prior-year period:
| Financial Metric | Q1 2025 | Q1 2026 | Year-over-Year Change (%) | Source |
|---|---|---|---|---|
| Net Sales ($ in thousands) | $9,710 | $8,722 | -10.18% | [6, 25] |
| Gross Profit ($ in thousands) | $5,538 | $5,282 | -4.62% | [6] |
| Gross Profit Margin (%) | 57.0% | 60.6% | +360 bps | [1, 6] |
| Operating Income ($ in thousands) | $3,153 | $2,565 | -18.65% | [6] |
| Operating Margin (%) | 32.5% | 29.4% | -310 bps | [6, 23] |
| Other Non-Operating Income ($) | $705 | $617 | -12.48% | [6] |
| Provision for Income Taxes ($) | $817 | $578 | -29.25% | [6] |
| Net Income ($ in thousands) | $3,041 | $2,604 | -14.37% | [6] |
| Diluted Earnings Per Share ($) | $0.919 | $0.818 | -11.00% | [1, 6] |
Because Wall Street analysts do not actively cover or publish forecasts for UTMD, there were no official consensus revenue or EPS estimates to beat, meet, or miss.[13, 26] Management did not issue any changes to guidance, reiterating that full-year 2026 results are expected to align with initial projections of flat revenue.[7, 27]
Following the announcement, UTMD shares fell 2.5% the next day to close at $67.87.[28] Over a broader post-earnings tracking period, the stock fell 4.3%, underperforming the S&P 500's gain of 0.6% over the same period.[27]
Geographically, domestic sales remained virtually flat, declining just 0.4% year-over-year.[6, 27] Outside the United States (OUS), trade sales dropped 23.4%.[27] This decline was primarily driven by the expected complete loss of blood pressure monitoring kit sales to its former Chinese distributor, alongside lower international sales of the Filshie Clip System.[6, 23] In Q1 2025, the combined sales to the Chinese distributor and the OEM partner PendoTECH totaled $857 thousand, meaning their loss accounted for 87% of the total $987 thousand year-over-year revenue decline in Q1 2026.[6, 23]
Product segment highlights in Q1 2026 were mixed [27]:
* Direct Domestic Clinical Sales: Decreased 12.8% ($503 thousand lower) to represent 61% of total domestic sales, indicating a temporarily weak demand quarter.[1]
* Domestic OEM Sales: Slid 2.1% ($13 thousand lower), representing 11% of domestic sales, following the final shipment of a $69 thousand backlog to PendoTECH in the prior-year quarter.[1]
* Domestic Filshie Device Sales: Surged 47.4% ($493 thousand higher), representing 28% of total domestic sales, driven by elevated clinical demand.[1]
Operating expenses rose to $2.717 million in Q1 2026, up from $2.385 million in the prior-year period.[6] Selling, general, and administrative (SG&A) expenses increased 14.9% to $2.563 million [6], driven by:
* A $127 thousand increase in litigation expenses, totaling $441 thousand.[6]
* A $147 thousand increase in domestic employee health insurance costs.[6, 23]
* A $65 thousand foreign exchange headwind on OUS operating expenses.[6, 23]
Non-operating income declined by $88 thousand, primarily due to lower interest yields on the company's cash balances.[6] However, a lower corporate income tax rate of 18.2% (compared to 21.2% in Q1 2025), driven by a more favorable mix of profits from the Irish subsidiary (taxed at 12.5% versus 25.45% in the U.S.), partially offset the drop in earnings before taxes.[6]
UTMD's stock closed at $72.78 as of July 6, 2026, representing a trailing price-to-earnings (P/E) multiple of 20.52x, a price-to-sales (P/S) multiple of 6.22x, and a price-to-book (P/B) multiple of 1.93x.[25, 29] With a total cash and investment balance of $87.406 million and total debt of just $210 thousand (representing a minor lease liability), the company has an enterprise value of approximately $148.33 million.[6, 30] Based on its trailing twelve-month EBITDA of $16.788 million, the company trades at a highly defensive EV/EBITDA multiple of 8.84x.[1]
Stagnant sales have historically limited the stock's valuation multiples.[7, 13] The company's 5-year sales performance demonstrates a clear downward trend:
5-Year Sales Trend ($ in Millions)
$55M +-------------------------------------------------------------------------+
| |
$50M |--- $49.05M --------- $52.28M --------- $50.22M |
| \ |
$45M | \ |
| \ |
$40M | --- $40.90M |
| \ |
$35M | --- $38.52M
+-------------------------------------------------------------------------+
FY2021 FY2022 FY2023 FY2024 FY2025
This represents a negative compound annual growth rate (CAGR) of 5.8%.[8, 9] Investors must evaluate UTMD's valuation based on its cash generation rather than top-line growth.[5] Operating cash flow remains strong, totaling $13.34 million over the trailing twelve months, which easily covers the current dividend payout of $1.24 per share.[30, 31] Management has also protected EPS through share repurchases, reducing diluted shares outstanding from 3.31 million in Q1 2025 to 3.18 million in Q1 2026.[6]
The primary execution risk is UTMD's ongoing transition from wholesale OEM distribution to a direct sales model for its high-pressure transducers.[14] Replicating PendoTECH’s former sales channels is a slow, capital-intensive process that requires direct sales outreach to biopharma manufacturing clients globally.[7, 14]
Furthermore, the company faces internal control risks within its small international subsidiaries.[7, 32] This was highlighted by a $0.2 million embezzlement charge recorded in its Australian subsidiary during the fourth quarter of 2025, showing that its lean administrative overhead can sometimes compromise financial oversight.[32]
Competitive risks are elevated by the threat of clients bringing manufacturing in-house.[10, 14] PendoTECH’s transition to its own transducer manufacturing eliminated a highly predictable revenue stream.[10, 14] If other major clinical OEM partners decide to replicate UTMD's proprietary designs, the company could face further structural revenue declines.[7]
Product concentration is the company's single largest structural vulnerability, with the Gynecology segment—primarily the Filshie Clip System—representing 51% of total sales ($19.719 million) in fiscal year 2025.[4] Any disruption to the supply chain or decline in clinical demand for this single product line would directly threaten overall profitability.[4]
The company remains exposed to persistent product liability lawsuits involving the Filshie Clip System.[2, 33, 34] Plaintiffs' attorneys allege that the clips are defectively designed, with a tendency to migrate from the fallopian tubes to cause chronic pain, organ damage, and complications that require surgical intervention.[33, 34]
Filshie Clip Litigation Funnel
+---------------------------------------------+
| 117 Total Claimants Historically (2023) |
+----------------------+----------------------+
|
v
+----------------------+----------------------+
| 19 Active Court Cases (Early 2026) |
+----------------------+----------------------+
|
v
+----------------------+----------------------+
| 15 Case Dismissals (Mid-2026) |
+----------------------+----------------------+
|
v
+----------------------+----------------------+
| 4 Remaining Open Cases (No Trials Yet) |
+---------------------------------------------+
Historically, 117 claimants were represented across these lawsuits.[2] While UTMD has successfully dismissed most of these claims (with 15 of 19 court cases dismissed by mid-2026 without going to trial), defending the product continues to incur high legal costs.[2, 32, 35] Q1 2026 litigation expenses rose to $441 thousand, up from $314 thousand in Q1 2025.[6] An unfavorable court ruling or a forced product recall would damage the business model.[33, 34]
With $87.406 million in cash and investments [6] representing 37.6% of its market capitalization [30], UTMD faces capital allocation challenges. This cash balance drags down the company's Return on Equity (ROE), which is currently 9.14%.[30] While a large cash reserve protects the dividend, keeping significant cash on the balance sheet during inflationary periods limits long-term shareholder value creation.[10]
Healthcare consolidation poses ongoing risks.[36] The growing influence of Group Purchasing Organizations (GPOs) in the United States squeezes the pricing power of niche suppliers.[11] Additionally, geographic isolation can impact sales, as seen in Canada where distributors have faced pressure from local medical facilities to avoid purchasing U.S.-manufactured medical devices.[37]
UTMD is highly sensitive to foreign exchange fluctuations, particularly the EUR, GBP, AUD, and CAD against the USD.[6, 38, 39] In Q1 2026, a weaker USD increased OUS operating expenses by $65 thousand.[6, 23] In addition, import tariffs put in place by the U.S. government have historically triggered reciprocal tariffs abroad, making UTMD’s exports more expensive and less competitive internationally.[4]
The company's risk profile can be monitored across three distinct levels of concern:
This five-year scenario model evaluates UTMD's potential performance through fiscal year 2031 (Year 5), using its fiscal year 2025 revenue of $38.52 million [7] and current outstanding share count of 3.184 million as a baseline.[6]
In the Base Case, UTMD's top-line stabilizes as its new direct biopharma sales channel gradually replaces lost OEM revenues.[7, 14] Sales grow at a modest 2.0% CAGR from FY2026 through FY2031, reaching $42.53 million. Net profit margins stabilize at 29.0%, supported by strong operating margins and interest income on cash balances.[7, 30] Year 5 Net Income reaches $12.33 million.
The company continues to use its excess cash flow to repurchase approximately 1.5% of its shares outstanding annually, reducing the share count to 2.95 million by Year 5. This drives Year 5 EPS to $4.18. Applying a P/E multiple of 20.0x (reflecting stable cash flows but limited growth) results in an implied share price of $83.60. Factoring in cumulative dividend payments of $1.24 per share annually ($6.20 total) [31], the total return is 23.4% (4.3% annualized).
In the High Case, UTMD’s transition to direct biopharma distribution accelerates faster than expected.[14] At the same time, the company launches new products and resolves its outstanding Filshie Clip litigation, driving down legal expenses.[2, 7] Sales grow at a 5.0% CAGR, reaching $49.16 million by Year 5. Net profit margins expand to 31.0% due to operating leverage and lower litigation costs.[6, 7] Year 5 Net Income reaches $15.24 million.
UTMD accelerates its share buyback program, repurchasing 3.0% of its shares outstanding annually to reduce the share count to 2.73 million by Year 5. This drives Year 5 EPS to $5.58. The market rewards this stronger growth and reduced litigation risk with multiple expansion, pushing the P/E to 22.0x. This yields an implied share price of $122.76. Including cumulative dividends of $6.50, the total return is 77.6% (12.2% annualized).
In the Low Case, the Filshie Clip litigation escalates, resulting in higher legal expenses and market share loss.[33, 34] OUS direct sales continue to contract, and the biopharma sensor business struggles to gain traction against larger competitors.[7, 14] Sales decline at a -3.0% CAGR to $33.08 million by Year 5. High legal expenses and poor manufacturing cost absorption drag net margins down to 25.0%, resulting in Year 5 Net Income of $8.27 million.
Capital allocation is conservative, with share repurchases slowed to 1.0% annually, leaving 3.02 million shares outstanding. Year 5 EPS drops to $2.74. Valuation multiples compress to 15.0x P/E due to litigation uncertainty and declining sales. This results in an implied share price of $41.10. Including cumulative dividends of $5.00, the total return is -36.7% (-8.7% annualized).
The projected share price trajectory in USD over the five-year forecast horizon is detailed below:
| Year of Projection | Base Case Price ($) | High Case Price ($) | Low Case Price ($) | Source Baseline |
|---|---|---|---|---|
| Year 0 (Current) | $72.78 | $72.78 | $72.78 | [29] |
| Year 1 | $72.80 | $89.54 | $44.55 | Projected model |
| Year 2 | $75.40 | $96.80 | $43.50 | Projected model |
| Year 3 | $78.00 | $104.94 | $42.60 | Projected model |
| Year 4 | $80.80 | $113.52 | $41.85 | Projected model |
| Year 5 (Implied Future) | $83.60 | $122.76 | $41.10 | Projected model |
The following table summarizes the operational assumptions and implied valuation models across the three scenarios:
| Scenario | Year 5 Revenue ($ Millions) | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price ($) | Implied Future Share Price ($) | 5-Year Total Return (%) | Annualized Return (%) | Probability Weight (%) |
|---|---|---|---|---|---|---|---|---|
| Base Case | $42.53 | 29.0% Net Margin / $4.18 EPS | 20.0x P/E | $72.78 | $83.60 | 23.4% | 4.3% | 55% |
| High Case | $49.16 | 31.0% Net Margin / $5.58 EPS | 22.0x P/E | $72.78 | $122.76 | 77.6% | 12.2% | 20% |
| Low Case | $33.08 | 25.0% Net Margin / $2.74 EPS | 15.0x P/E | $72.78 | $41.10 | -36.7% | -8.7% | 25% |
By weighting these outcomes (55% Base, 20% High, 25% Low), the probability-weighted target price is calculated as:
$\text{Target Price} = (0.55 \times \$83.60) + (0.20 \times \$122.76) + (0.25 \times \$41.10) = \$80.81$
This probability-weighted target of $80.81 represents an 11.0% upside relative to the current share price of $72.78, excluding dividend yields.
STABLE CAPITAL RETURN
This qualitative evaluation assesses UTMD's core business quality and operational metrics on a scale of 1 to 10:
Combining these ten ratings yields a blended qualitative score of 6.4 out of 10.
CONSERVATIVE CASH GENERATOR
Utah Medical Products represents a unique, defensive deep-value play within the medical device sector. The investment thesis relies on several key factors:
Core Investment Thesis Pillars
+-------------------------------------------------------------------------------+
| High Profitability: Consistent ~60% gross and ~30% net margins |
+-------------------------------------------------------------------------------+
| Asset Underpinning: Cash represents ~37.6% of the company's market cap |
+-------------------------------------------------------------------------------+
| Litigation Resolution: 15 of 19 Filshie Clip lawsuits successfully dismissed |
+-------------------------------------------------------------------------------+
| Valuation Support: Low EV/EBITDA multiple of 8.84x |
+-------------------------------------------------------------------------------+
The company's stagnant top-line growth is a known concern.[8] However, this is offset by its exceptionally strong balance sheet, with cash and investments representing over a third of its total valuation.[6, 30] Furthermore, UTMD maintains elite profitability, with a gross margin of 60.6% and a net income margin of 29.9% as of Q1 2026.[1, 6]
Key catalysts that could unlock value over the next five years include:
* The successful transition to a direct-to-biopharma sales model, which would replace lost wholesale OEM revenue with higher-margin direct sales.[7, 14]
* The resolution of remaining Filshie Clip lawsuits, which would lower SG&A expenses and reduce overall litigation risk.[6, 35]
* A more active capital allocation strategy, such as a special dividend or larger share buybacks, to deploy the company's excess cash reserves.[10]
While top-line growth remains limited, the downside is highly protected by the company's debt-free balance sheet, strong cash reserves, and depreciated real estate assets.[1, 10] At an EV/EBITDA multiple of 8.84x, the shares are highly defensive and well-positioned to deliver stable income and steady capital returns.[1, 35]
HIGHLY DEFENSIVE VALUE
UTMD's stock is currently trading above its 50-day moving average of $66.53 and its 200-day moving average of $62.35, demonstrating strong upward price momentum over the past year.[13, 30] The stock has risen from its 52-week low of $53.66 and is currently trading near its 52-week high of $75.75.[30] This positive price action is supported by the company's stable Q1 2026 operating performance, ongoing share buybacks, and its latest quarterly dividend increase.[1, 23, 31]
BULLISH CONSOLIDATION
View Utah Medical Products, Inc. (UTMD) stock page
Loading the interactive version of this report…